Wells Fargo & Company Arcturus Therapeutics Holdings Inc. Transaction History

Wells Fargo & Company

$507 Billion
Q3 2025

A detailed history of Wells Fargo & Company transactions in Arcturus Therapeutics Holdings Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 33,235 shares of ARCT stock, worth $241,618. This represents 0.0% of its overall portfolio holdings.

Number of Shares

33,235

Previous 22,446 48.07%

Holding current value

$241,618

Previous $292,000 109.59%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$11.39 - $22.17 $122,886 - $239,192	10,789 Added 48.07%	33,235 $612,000
Q2 2025 Aug 14, 2025	BUY	$8.91 - $14.41 $34,018 - $55,017	3,818 Added 20.5%	22,446 $292,000
Q1 2025 May 13, 2025	SELL	$10.59 - $20.83 $540,471 - $1.06 Million	-51,036 Reduced 73.26%	18,628 $197,000
Q4 2024 Feb 12, 2025	BUY	$14.82 - $25.48 $115,373 - $198,361	7,785 Added 12.58%	69,664 $1.18 Million
Q3 2024 Nov 13, 2024	SELL	$18.08 - $25.38 $197,198 - $276,819	-10,907 Reduced 14.99%	61,879 $1.44 Million

Q2 2024 Aug 13, 2024	BUY	$24.35 - $44.39 $27,466 - $50,071	1,128 Added 1.57%	72,786 $1.77 Million
Q1 2024 May 10, 2024	SELL	$31.23 - $42.99 $41,036 - $56,488	-1,314 Reduced 1.8%	71,658 $2.42 Million
Q4 2023 Feb 09, 2024	SELL	$17.71 - $32.97 $668,428 - $1.24 Million	-37,743 Reduced 34.09%	72,972 $2.3 Million
Q3 2023 Nov 13, 2023	SELL	$25.44 - $37.35 $1.09 Million - $1.6 Million	-42,880 Reduced 27.92%	110,715 $2.83 Million
Q2 2023 Aug 15, 2023	SELL	$23.94 - $32.36 $168,609 - $227,911	-7,043 Reduced 4.38%	153,595 $4.41 Million
Q1 2023 May 12, 2023	BUY	$14.72 - $23.97 $647,915 - $1.06 Million	44,016 Added 37.74%	160,638 $3.85 Million
Q4 2022 Feb 13, 2023	SELL	$14.14 - $23.06 $956,797 - $1.56 Million	-67,666 Reduced 36.72%	116,622 $1.98 Million
Q3 2022 Nov 14, 2022	BUY	$13.05 - $22.13 $106,213 - $180,116	8,139 Added 4.62%	184,288 $2.73 Million
Q2 2022 Aug 12, 2022	BUY	$12.26 - $31.17 $239,437 - $608,750	19,530 Added 12.47%	176,149 $2.77 Million
Q1 2022 May 16, 2022	BUY	$17.64 - $39.57 $628,425 - $1.41 Million	35,625 Added 29.44%	156,619 $4.22 Million
Q4 2021 Feb 14, 2022	SELL	$34.2 - $47.56 $631,434 - $878,100	-18,463 Reduced 13.24%	120,994 $4.48 Million
Q3 2021 Nov 15, 2021	BUY	$27.88 - $58.25 $592,143 - $1.24 Million	21,239 Added 17.97%	139,457 $6.66 Million
Q2 2021 Aug 16, 2021	BUY	$25.79 - $42.11 $260,117 - $424,721	10,086 Added 9.33%	118,218 $4 Million
Q1 2021 May 13, 2021	SELL	$38.75 - $86.92 $1.29 Million - $2.89 Million	-33,240 Reduced 23.51%	108,132 $4.47 Million
Q4 2020 Feb 09, 2021	BUY	$34.61 - $123.66 $2.26 Million - $8.08 Million	65,321 Added 85.89%	141,372 $6.13 Million
Q3 2020 Nov 05, 2020	BUY	$37.49 - $63.19 $410,627 - $692,120	10,953 Added 16.83%	76,051 $3.26 Million
Q2 2020 Aug 13, 2020	BUY	$12.66 - $58.27 $623,365 - $2.87 Million	49,239 Added 310.48%	65,098 $3.04 Million
Q1 2020 May 14, 2020	BUY	$9.31 - $18.26 $147,647 - $289,585	15,859 New	15,859 $216,000

Others Institutions Holding ARCT

# of Institutions

173

Shares Held

26M

Call Options Held

2.32M

Put Options Held

866K

View Full List

About Arcturus Therapeutics Holdings Inc.

Ticker ARCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,576,400
Market Cap $193M
Description
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...

More about ARCT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Arcturus Therapeutics Holdings Inc. Transaction History